RxDoctor Payments Data

Pamela Himstedt

Family · Cape Girardeau, MONPI 1164690236

Payments from drug & device makers

$1,836in general payments, 2019–2025

Across 100 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$338
  • Amgen$190
  • Paratek Pharmaceuticals, Inc.$150
  • AstraZeneca$147
  • Novo Nordisk$113
  • Axsome Therapeutics, Inc.$110
  • plus $788 from 19 others

What the payments were for

  • Food & beverage$1,836100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,836 in reported general payments places this provider in the 75th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$127,875
Medicare patients
261
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide32$34,557
FarxigaDapagliflozin Propanediol85$24,454
TrulicityDulaglutide17$17,566
TradjentaLinagliptin68$17,010
EliquisApixaban42$12,420
JardianceEmpagliflozin35$11,257
GemtesaVibegron35$8,564
Potassium Chloride184$8,003
DuleraMometasone/Formoterol15$5,572
EntrestoSacubitril/Valsartan12$3,864
DapagliflozinDapagliflozin Propanediol12$3,350
Divalproex Sodium27$2,337
Methenamine Hippurate19$1,918
Rosuvastatin Calcium128$1,555
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$1,555

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$338$52,12349 claims
Boehringer IngelheimTradjenta, Jardiance$37$28,267103 claims
AstraZenecaFarxiga$147$24,45485 claims
PfizerEliquis$17$12,42042 claims
Sumitomo Pharma America, Inc.Gemtesa$32$8,56435 claims
NovartisEntresto$27$3,86412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,812 family providers in Missouri.

Other family in Cape Girardeau

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →